PDLLA vs PCL
This page places verifiable specifications side by side. It does not rank materials, score them, or recommend one over another.
Comparison
How does PCL stimulate collagen compared to PDLLA?
Both are aliphatic polyesters delivered as particles, and the literature describes the same broad sequence for each: a foreign-body response to the particle, fibroblast activity, then matrix deposition. The materials differ in repeat unit and in reported breakdown time, which the literature describes as longer for PCL. Neither has an established regulatory classification in the United States; in Korea and the European Union both follow the device route.
| Aspect | PDLLA (Poly-D,L-lactic acid) | PCL (Polycaprolactone) | Basis |
|---|---|---|---|
| Repeat unit | Lactic acid | Caprolactone | — |
| Reported sequence in the literature | Foreign-body response to the particle, fibroblast activity, extracellular matrix deposition | Controlled foreign-body reaction to the microsphere, fibroblast activity, new collagen formation | — |
| Particle form described | Amorphous microspheres | Smooth spherical microspheres in a carrier reported as carboxymethylcellulose | — |
| Reported breakdown time | Formulation-specific; figures are not standardised between manufacturers | Described in the literature as longer than for lactic-acid-based polyesters; chain length is linked to the reported duration | — |
| Direct tissue measurement cited | Animal work reporting angiogenesis and collagen synthesis in aged skin (PMID 37175693) | Human biopsy study reporting increased dermal thickness after a single intradermal injection (PMID 30778526) | — |
| Regulatory identity — Korea | Medical device, tissue-repair biomaterial route | Medical device, tissue-repair biomaterial route | Legal text |
| Regulatory identity — European Union | Medical device under MDR Annex XVI, Section 3 | Medical device under MDR Annex XVI, Section 3 | Legal text |
| Regulatory identity — United States | Not established from public sources | Not established from public sources; no premarket approval record was found for a polycaprolactone dermal implant | — |
| Randomised trial cited on this site | PMID 39178357 — evaluator-blinded multicentre comparison | PMID 36191597 — multicentre trial against sodium hyaluronate for nasolabial folds | — |
The mechanism described is the same shape
For both materials the literature reports the same sequence: a particle is placed in the dermis, the host mounts a foreign-body response, fibroblasts become active, and matrix is deposited. Neither material is described as supplying collagen. What differs is the chemistry of the particle and how long it is reported to remain.
Where the evidence differs in kind
The tissue-level evidence is not of the same type. For PDLLA the collagen finding cited here comes from animal work; for PCL it comes from a human biopsy study, where dermal thickness was measured after a single intradermal injection. A human histology reading and an animal model answer different questions, so the two rows should not be read as one being confirmed further than the other.
Regulatory position
In Korea and the European Union the two materials are handled through the same route. In the United States neither could be established from public records — for PCL specifically, no premarket approval record for a dermal implant was found in the agency device database. Absence of a record is not a classification, which is why the table marks it as not established rather than drawing a conclusion.
Limitations & open questions
No study cited here places the two materials in the same protocol, so the rows describing breakdown time draw on separate formulations rather than a controlled comparison. The randomised evidence for each material uses a different comparator — one against no treatment or another biostimulator, the other against a hyaluronic acid filler — which means the trial results are not interchangeable. Delayed nodule and granuloma cases have been described for PCL in the literature.